Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9) The purpose of this assay is to identify compounds that act as inhibitors of RBBP9. In this assay, a fluorophosphonate-rhodamine (FP-Rh) probe which broadly targets enzymes from the serine hydrolase family is used to label RBBP9 in the presence of test compounds. The reaction is excited with linear polarized light and the intensity of the emitted light is measured as the polarization value (mP). As designed, test compounds that act as RBBP9 inhibitors will prevent RBBP9-probe interactions, thereby increasing the proportion of free (unbound) fluorescent probe in the well, leading to low fluorescence polarization in the well. Compounds were tested in singlicate at a final nominal concentration of 7.94 micromolar. Protocol Summary: Prior to the start of the assay, 4.0 ul of Assay Buffer (0.1% Pluronic acid, 50 mM Tris HCl, 150 mM NaCl, pH 8.0) containing 2.5 uM of RBBP9 protein were dispensed into 1536 microtiter plates. Next, 40 nL of test compound in DMSO or DMSO alone (0.794% final concentration) were added to the appropriate wells and incubated for 30 minutes at 25 degrees Celsius. The assay was started by dispensing 1.0 ul of 375 nM FP-Rh probe in Assay Buffer to all wells. Plates were centrifuged and after 45 minutes of incubation at 25 degrees Celsius, fluorescence polarization was read on a Viewlux microplate reader (PerkinElmer, Turku, Finland) using a BODIPY TMR FP filter set and a BODIPY dichroic mirror (excitation = 525nm, emission = 598nm). Fluorescence polarization was read for 30 seconds for each polarization plane (parallel and perpendicular). The well fluorescence polarization value (mP) was obtained via the PerkinElmer Viewlux software. The percent inhibition for each compound was calculated as follows: Percent inhibition = (Test_Compound_mP -median_Positive_Control_mP) / (median_Negative_Control_mP - median_Positive_Control_mP)*100 Where: Negative_Control is defined as wells containing RBBP9 and DMSO, Test_Compound is defined as wells containing RBBP9 in the presence of test compound, Positive_Control is defined as wells containing no RBBP9 protein. A mathematical algorithm was used to determine nominally inhibiting compounds in the primary screen. Two values were calculated: (1) the average percent inhibition of all compounds tested, and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter, i.e. any compound that exhibited greater % inhibition than the cutoff parameter was declared active. The inactive compounds of this assay have activity score range of 0 to 6 and active compounds range of activity score is 6 to 100. The reported PubChem Activity Score has been normalized to 100% observed primary inhibition. Negative % inhibition values are reported as activity score zero. List of Reagents: Recombinant RBBP9 (supplied by Assay Provider) FP-Rh probe (supplied by Assay Provider) Tris HCl (Sigma, part T3038) NaCl (Sigma, part S6546) Pluronic acid (Invitrogen, part P6866) 1536-well plates (Greiner, part 789176)
bao:BAO_0001067 "1537" ; # "is primary assay of" -> "1537"
bao:BAO_0001067 "1947" ; # "is primary assay of" -> "1947"
bao:BAO_0001067 "1974" ; # "is primary assay of" -> "1974"
bao:BAO_0001067 "1978" ; # "is primary assay of" -> "1978"
bao:BAO_0001067 "2176" ; # "is primary assay of" -> "2176"
bao:BAO_0001067 "2243" ; # "is primary assay of" -> "2243"
bao:BAO_0001067 "2269" ; # "is primary assay of" -> "2269"
bao:BAO_0000812 "1790" ; # "has summary assay" -> "1790"
bao:BAO_0000812 "2248" ; # "has summary assay" -> "2248"
bao:BAO_0000812 "2299" ; # "has summary assay" -> "2299"
bao:BAO_0000808 bao:BAO_0000031 ; # "has primary assay" -> "primary assay"
bao:BAO_0000205 bao:BAO_0000217 ; # "has assay format" -> "biochemical format"
bao:BAO_0000205 bao:BAO_0000224 ; # "has assay format" -> "protein format"
bao:BAO_0000205 bao:BAO_0000357 ; # "has assay format" -> "single protein format"
bao:BAO_0000409 bao:BAO_0000410 ; # "assay measurement type" -> "endpoint assay"
bao:BAO_0002850 bao:BAO_0000534 ; # "has assay readout content" -> "single readout"
bao:BAO_0002851 "single parameter" ; # "has assay readout content parametricity" -> "single parameter"
bao:BA0_0090012 bao:BAO_0000222 ; # "has participant" -> "generic hydrolase" || bao:BAO_0003102 bao:BAO_00020144 ; # "has role" -> "target"
bao:BAO_0002855 bao:BAO_0000110 ; # "is bioassay type of" -> "protein-small molecule interaction assay"
bao:BAO_0000212 bao:BAO_0000123 ; # "has assay method" -> "binding assessment method"
bao:BAO_0000207 bao:BAO_0000003 ; # "has detection method" -> "fluorescence polarization"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "To identify inhibitors of Retinoblastoma binding protein 9 (RBBP9)" ; # "screening campaign name" -> "To identify inhibitors of Retinoblastoma binding protein 9 (RBBP9)"
bao:BAO_0002853 "Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9)" ; # "has assay title" -> "Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9)"
bao:BAO_0003105 <http://purl.obolibrary.org/obo/GO_0005488> ; # "has function" -> "binding"
bao:BAO_0002867 bao:BAO_0000516 ; # "has assay footprint" -> "1536 well plate"
bao:BAO_0002863 bao:BAO_0000536 ; # "has concentration throughput" -> "single concentration"
bao:BAO_0000109 "25 degree celsius" ; # "has temperature value" -> "25 degree celsius"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "25 degree celsius" ; # "substrate incubation temperature" -> "25 degree celsius"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "45 minute" ; # "substrate incubation time" -> "45 minute"
bao:BAO_0002833 "30 minute" ; # "has incubation time value" -> "30 minute"
bao:BA0_0090012 "no RBBP9 protein" ; # "has participant" -> "no RBBP9 protein"
bao:BAO_0000740 bao:BAO_0000080 ; # "has assay control" -> "positive control"
bao:BA0_0090012 bao:BAO_0000118 ; # "has participant" -> "DMSO"
bao:BAO_0000740 bao:BAO_0000079 ; # "has assay control" -> "negative control"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Benjamin Cravatt" ; # "material entity assay provider" -> "Benjamin Cravatt" || bao:BAO_0003102 bao:BAO_0000027 ; # "has role" -> "assay provider"
bao:BAO_0002020 bao:BAO_0000372 ; # "has assay phase characteristic" -> "homogeneous phase"
bao:BA0_0090012 bao:BAO_0000694 ; # "has participant" -> "Tris" || bao:BAO_0003102 <http://purl.obolibrary.org/obo/CHEBI_35225> ; # "has role" -> "buffer"
bao:BA0_0090012 bao:BAO_0000995 ; # "has participant" -> "Pluronic F-127" || bao:BAO_0003102 <http://purl.obolibrary.org/obo/CHEBI_27780> ; # "has role" -> "detergent"
bao:BA0_0090012 bao:BAO_0000914 ; # "has participant" -> "Fluorophosphonate-rhodamine" || bao:BAO_0003102 bao:BAO_00020143 ; # "has role" -> "substrate"
bao:BA0_0090012 "Putative hydrolase RBBP9" ; # "has participant" -> "Putative hydrolase RBBP9"
bao:BAO_0002921 <http://purl.obolibrary.org/obo/NCBITaxon_9606> ; # "has organism" -> "Homo sapiens"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "10741" ; # "gene ID" -> "10741"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "O75884" ; # "uniprot ID" -> "O75884"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "9606" ; # "NCBI taxonomy ID" -> "9606"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "10741" ; # "construct gene ID" -> "10741"
bao:BAO_0002662 bao:BAO_0002157 ; # "has quality" -> "native form"
bao:BAO_0002897 bao:BAO_0000360 ; # "has preparation method" -> "recombinant expression"
bao:BAO_0002000 bao:BAO_0002001 ; # "has measured entity" -> "measured entity"
bao:BAO_0002857 bao:BAO_0000261 ; # "has signal direction" -> "signal decrease corresponding to inhibition"
bao:BA0_0090012 bao:BAO_0000176 ; # "has participant" -> "small molecule" || bao:BAO_0003102 bao:BAO_00020137 ; # "has role" -> "perturbagen"
bao:BAO_0000212 bao:BAO_0000574 ; # "has assay method" -> "single perturbagen"
bao:BAO_0002865 bao:BAO_0000691 ; # "uses detection instrument" -> "ViewLux ultraHTS Microplate Imager"
bao:BAO_0000737 bao:BAO_0000297 ; # "has manufacturer" -> "Perkin Elmer" || bao:BAO_0003102 bao:BAO_0002628 ; # "has role" -> "instrumentation manufacturer"
bao:BAO_0002917 "525 nanometer" ; # "has excitation wavelength value" -> "525 nanometer"
bao:BAO_0002918 "598 nanometer" ; # "has emission wavelength value" -> "598 nanometer"
bao:BAO_0000337 bao:BAO_0000201 ; # "has percent response" -> "percent inhibition"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "1" ; # "PubChem TID" -> "1"
bao:BAO_0000182 <http://purl.org/obo/owl/UO#UO_0000187> ; # "has response unit" -> "percent"
bao:BAO_0002666 "7.94" ; # "has concentration value" -> "7.94"
bao:BAO_0000183 <http://purl.org/obo/owl/UO#UO_0000064> ; # "has concentration unit" -> "micromolar"
bao:BAO_0002787 "1" ; # "has concentration-point number" -> "1"
bao:BAO_0002845 "1" ; # "has repetition point-number" -> "1"
bao:BAO_0000196 bao:BAO_0000091 ; # "has mode of action" -> "inhibition"
bao:BAO_0002864 bao:BAO_0000136 ; # "has repetition throughput" -> "single repetition"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "kunie-2" ; # "Annotated by" -> "kunie-2"
